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Purpose: Recent findings of increased cathelicidin protein and its proteolytic frag-
ments in rosacea suggest a pathogenic role for cathelicidin in this disease. The re-
lationship between cathelicidin and protease-activated receptor 2 (PAR-2) is there-
fore of interest, as PAR-2, expressed principally in keratinocytes, regulates pro-
inflammatory cytokine expression in the skin. The purpose of this study was to 
determine the relationship between expression of PAR-2 and cathelicidin in rosa-
cea and to test the effect of direct PAR-2 activation on cathelicidin expression in 
keratinocytes. Materials and Methods: Samples from 40 patients with clinico-
pathologic diagnosis of rosacea and facial skin tissue samples from 20 patients 
with no specific findings or milium without inflammation were retrieved. Intensi-
ties of immunohistochemical staining for PAR-2 and cathelicidin were compared 
between normal and rosacea-affected skin tissues. Additionally, correlations be-
tween PAR-2 and cathelicidin staining intensities within rosacea patients were ana-
lyzed. In cultured keratinocytes, changes in PAR-2, cathelicidin, and vascular en-
dothelial growth factor (VEGF) mRNA and protein were analyzed after treatment 
with PAR-2 activating peptide (AP). Results: Cathelicidin expression was signifi-
cantly higher in rosacea skin tissues than in normal tissues (p<0.001), while PAR-
2 expression was not significantly higher in rosacea tissues than in normal skin tis-
sues. A positive correlation between PAR-2 and cathelicidin within rosacea samples 
was observed (R=0.330, p=0.037). After treatment of PAR-2 AP, both mRNA and 
protein levels for PAR-2, cathelicidin, and VEGF significantly increased in cul-
tured keratinocytes, compared with PAR-2 control peptide treatment. Conclusion: 
PAR-2 may participate in the pathogenesis of rosacea through activation of cathe-
licidin LL-37, a mediator of innate immune responses in the skin.
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INTRODUCTION
Rosacea is a common inflammatory skin disease, most prominent in the central 
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MATERIALS AND METHODS
Patient samples
The Institutional Review Board of Severance Hospital ap-
proved this study (No. 4-2012-0191). Data for the 40 pa-
tients diagnosed with rosacea at the Department of Derma-
tology, Yonsei University College of Medicine from 2005 
to 2010 were reviewed. The diagnosis of rosacea was based 
on clinical photos and medical charts together with patho-
logical findings. For comparison, 20 samples of facial skin 
diagnosed as no specific findings or milium without inflam-
mation were selected for review. 
Cell culture and reagents
Cells of the immortalized human keratinocyte cell line Ha-
CaT were maintained in Dulbecco’s Modified Eagle’s medi-
um (Welgene, Daegu, Korea) supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin at 37°C in a 
humidified CO2 incubator (95% air, 5% CO2). PAR-2 AP, 
SLIGKV-NH2 (Ser-Leu-Ile-Gly-Lys-Val) (Peptron, Dae-
jeon, Korea) was used to activate PAR-2. Reverse PAR-2 
control peptide (CP) (Peptron) was used to determine the 
specificity of effect of PAR-2 activators. PAR-2 AP (100 
μM) was added to HaCaT cells after replacing the culture 
medium with serum-free medium. In this time-dependent 
stimulation experiment, HaCaT cells were all plated at the 
same time, and PAR-2 was then added at the appropriate 
times thereafter. All HaCaT cells were simultaneously har-
vested 24 hours after plating. 
Histology and immunohistochemistry
Hematoxylin-eosin stained slides and paraffin-embedded 
tissues from each case were retrieved from the surgical files 
of the Department of Pathology. Each tissue was serially 
sliced into four sections 3 to 4 μm thick for immunohisto-
chemical analysis. Immunohistochemistry was performed 
using the polymer detection method (NovoLink Max Poly-
mer Detection System, Leica Biosystems, Newcastle Ltd., 
Newcastle, UK). 
Briefly, sections previously attached to silane-coated 
slides were dried at 60°C for 1 hr. The sections were depar-
affinized in xylene and rehydrated in graded alcohol and 
distilled water. For antigen retrieval, the sections were put 
into 10 mM citrate buffer (pH 6.0) and boiled in a micro-
wave oven. After cooling at room temperature, sections 
were treated with a peroxidase block kit for 15 min, washed 
area of the face, namely the cheeks, nose, chin, and fore-
head, which are densely populated with sebaceous glands.1 
Fair-skinned individuals suffer disproportionately from this 
disease with its chronic relapsing course. The disease is 
characterized by primary and secondary features: primary 
features include flushing, persistent erythema, telangiecta-
sia, as well as papules and pustules, while secondary fea-
tures consist of burning or stinging, plaques, dry appear-
ance, edema or phyma.2 The chronic inflammatory and 
vascular manifestations of rosacea point to a complex, mul-
tifactorial pathophysiology. Interestingly, recent findings 
suggest that an altered regulation of the innate immune re-
sponse may be involved.3 
Cathelicidins comprise a family of antimicrobial peptides 
(AMPs) expressed in leukocytes and in various epithelial 
tissues, where they participate in innate immune respons-
es.4,5 Some cathelicidin peptides, including LL-37 ex-
pressed in humans, express both vasoactive and proinflam-
matory activities.6,7 Significantly higher levels of cathelicidin 
peptides may be detected in rosacea-affected skin, com-
pared to healthy skin.8 Increased expression of the serine 
protease kallikrein 5 in the skin of patients with rosacea 
may promote proteolytic conversion of cathelicidin precur-
sor into the active cathelicidin peptide LL-37.8,9 Abnormal-
ly increased expression of LL-37 may induce vascular en-
dothelial growth factor (VEGF) in epidermal keratinocytes, 
which corresponds to the enhanced inflammation and vas-
cular response seen in rosacea.9,10 
Protease-activated receptor 2 (PAR-2), a PAR-family G-
protein-coupled 7-transmembrane domain receptor, is acti-
vated by serine proteases such as kallikrein, and PAR-2 me-
diates inflammation in various tissues.11-14 PAR-2 signaling 
may also promote expression of the epithelial antimicrobial 
peptides human β-defensin-2 (hBD-2) and LL-37 as com-
ponents of innate immunity.15,16 Although expression of the 
serine protease that activates PAR-2 is increased in rosacea, 
the regulation of PAR-2 and its role in rosacea remain un-
clear. 
We hypothesized that PAR-2 expression increases in the 
skin of patients with rosacea and that direct activation of 
PAR-2 would increase production of cathelicidin LL-37, 
which may participate in rosacea. To elucidate the role of 
PAR-2 in the pathogenesis of rosacea, we tested for correla-
tions between cathelicidin and PAR-2 expression in skin 
samples from patients with rosacea, as well as the induction 
of cathelicidin expression in cultured keratinocytes upon 
treatment with PAR-2 activating peptide (AP).
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(threshold cycle) method, where ∆Ct was (target Ct‒GAP-
DH Ct), and ∆∆Ct was (∆Ct sample‒∆Ct untreated con-
trol). The quantity of the sample relative to control mRNA 
was 2‒∆∆Ct. The mRNA expression was indicated with a 
Ct value and was corrected for GAPDH expression.
Western blotting
Whole cell extracts were prepared in RIPA buffer (TBS, 
0.5% deoxycholate, 0.1% SDS, 1% Triton X-100) containing 
protease inhibitor cocktail (Sigma, St. Louis, MO, USA). 
Proteins isolated from HaCaT cells after treatment with PAR-
2 AP were separated by SDS-PAGE on 15% gels, and then 
transferred to nitrocellulose membranes using standard pro-
cedures. The membranes were blocked with 5% v/v skim 
milk in a TBS-T buffer (TBS with 0.1% w/v Tween-20) and 
reacted with primary antibodies overnight at 4°C. Primary 
antibodies against PAR-2 (Santa Cruz Biotechnology), cathe-
licidin (Abcam), and VEGF (Santa Cruz Biotechnology, San-
ta Cruz, CA, USA) were used at a 1:1000 dilution. The mem-
branes were then washed three times for 15 min each with 
the TBS-T buffer and incubated for 1 hr with 1% skim milk 
in TBS-T buffer containing horseradish peroxidase-conjugat-
ed secondary antibodies (1:2000). The proteins were visual-
ized using an enhanced chemiluminescence system (Thermo 
Scientific, Bremen, Germany). GAPDH (Santa Cruz Bio-
technology) was used as a control for protein loading. 
Statistical analysis
Statistical analyses were performed using Statistical Pack-
age for the Social Sciences (SPSS Inc., Chicago, IL, USA) 
for Windows. Staining intensities of PAR-2 and cathelicidin 
were compared between normal and rosacea-affected skin 
using the Student’s t-test. The relationship between PAR-2 
and cathelicidin staining intensities was tested by Pearson 
correlation analysis. Differences in PAR-2, cathelicidin and 
VEGF expression between treatment with PAR-2 AP and 
PAR-2 CP were analyzed with the Student’s t-test. Signifi-
cance was analyzed at the level of 0.05.
 
RESULTS
 
Demographic and clinical findings of patients with 
rosacea
Among the 40 patients with rosacea enrolled in this study, 
10 were male and 30 were female. Their ages ranged from 
21 to 76 years (mean, 47.2±13.8 years). The physician clas-
with Tris-buffered saline (TBS) for 5 min, and incubated 
with primary antibodies at room temperature for 1 hr. 
The antibodies and dilutions used were as follows: PAR-
2 (rabbit polyclonal anti-human, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, 1:200) and cathelicidin (rabbit poly-
clonal anti-human, Abcam, Cambridge, MA, USA, 1:200). 
Slides were washed with TBS three times, and then reacted 
with Post Primary (included in the kit) at room temperature 
for 30 min. After washing with TBS three times, slides 
were reacted with polymer for 30 min. Color was devel-
oped using the NovaRED substrate kit (VECTOR Labora-
tory, Burlingame, CA, USA). The reaction was stopped 
with distilled water while being observed under a micro-
scope. Harris hematoxylin was used as a counterstain. 
Slides were examined at 400× magnification. Two inves-
tigators independently reviewed slides without knowledge 
of the clinical data. The intensity of keratinocytes showing 
immunoreactivity to each marker in more than three high 
powered fields was assessed semi-quantitatively using the 
following grading system: 0=no staining, 1=weak staining, 
2=moderate staining, and 3=strong staining.
Real-time RT-PCR analysis
Total RNA was extracted using the RNeasy mini-kit (Qia-
gen, Valencia, CA, USA) according to the manufacturer’s in-
structions. One microgram of total RNA was used as the first 
strand for cDNA synthesis with PrimescriptTM (TaKaRa Bio 
Inc., Otsu, Japan). For all quantitative real-time RT-PCR 
analyses, amplification was performed in a Step One Real-
Time PCR System (Applied Biosystems, Foster City, CA, 
USA) and visualized with a Power SYBR GREEN MAS-
TER MIX (Applied Biosystems). The cycling conditions 
were as follows: 2 min at 50°C, 10 min at 95°C, and 40 cy-
cles of 95°C for 15 seconds, and 60°C for 1 min. For each 
specific mRNA analysis, gene expression was normalized to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
mRNA in the same sample. The primer sequences used were 
as follows: PAR-2 forward, 5’-GGCCCTGTGGGTCTT 
TCTTTT-3’, and reverse, 5’-CAAGGGGAACCAGATGA 
CAGA-3’; forward 5’-GGCTGGTGAAGCGGTGTAT-3’, 
and reverse, 5’-TGGGTACAAGATTCCGCAAAAA-3’ 
(cathelicidin); forward, 5’-CGCAGCTACTGCCATCC 
AAT-3’, reverse, 5’-GTGAGGTTTGATCCGCATAATC 
T-3’ (VEGF); forward, 5’-GCTCCTCCTGTTCGACAGT 
CA-3’ and reverse, 5’-ACCTTCCATGGT GTCTGA-3’ 
(GAPDH).
Relative quantification was performed using the ∆∆Ct 
The Role of Protease-Activated Receptor 2 in Rosacea
Yonsei Med J   http://www.eymj.org   Volume 55   Number 6   November 2014 1651
treatment with PAR-2 AP (Fig. 5). 
DISCUSSION
The complex pathophysiology of rosacea suggests a multi-
factorial etiology with vascular and immunological compo-
nents underlying a chronic inflammatory response.18 Promi-
sified each patient by rosacea subtype and graded the severi-
ty of their disease. Twelve patients (30%) were diagnosed 
with erythematotelangiectatic rosacea (ETR) and 28 patients 
(70%) were diagnosed with papulopustular rosacea (PPR). 
No patients presented with the phymatous subtype. Of the 
40 patients, six patients (15%) were graded as mild, 24 
(60%) were graded as moderate, and 10 (25%) were graded 
as severe, based on the severity of erythema (Table 1).17
Immunoreactivity for PAR-2 and cathelicidin between 
rosacea skin and normal facial skin and the correlation 
between PAR-2 and cathelicidin staining in rosacea 
tissues
Histopathologically, vascular dilation with perivascular and 
perifollicular lymphohistiocytic inflammation of varying 
degrees was noted in the upper dermis of lesional skin from 
patients with rosacea. Mean staining intensities of PAR-2 
and cathelicidin in rosacea were 1.7±0.6 and 1.8±0.7, re-
spectively. Mean staining intensities of PAR-2 and catheli-
cidin in normal skin were 1.3±1.0 and 0.5±0.3, respectively. 
Cathelicidin expression in rosacea skin tissues was signifi-
cantly higher than that in normal tissues (p<0.001). Rosacea 
tissues showed detectably greater PAR-2 expression than 
normal skin tissues, although the difference did not reach 
statistical significance. Additionally, differences in staining 
intensities between PAR-2 and cathelicidin according to 
clinical severity were not significant (Table 2). However, a 
significant correlation between clinical severity and grade 
of inflammation was observed (p=0.018). As well, differ-
ences in expressions of PAR-2 and cathelicidin between 
subtypes of rosacea, such as ETR and PPR, were also not 
significant. 
The level of cathelicidin expression according to PAR-2 
expression was examined. As PAR-2 expression increased, 
a trend toward an increase in cathelicidin expression was 
shown (beta=0.330, p=0.037) (Fig. 1). In Figs. 2 and 3, two 
patients with rosacea who showed high expression of PAR-
2 and cathelicidin in affected skin tissues are presented to-
gether with their immunohistochemical findings. 
 
Expression of PAR-2, cathelicidin and VEGF in 
keratinocytes after treatment of PAR-2 AP 
After 24-hr incubation of keratinocytes with PAR-2 AP, the 
levels of PAR-2, cathelicidin, and VEGF mRNA were sig-
nificantly higher than those treated with PAR-2 CP (p<0.05) 
(Fig. 4). In Western blotting, increased levels of PAR-2, cat-
helicidin, and VEGF proteins were observed after a 24-hr 
Table 1. Demographic and Clinical Features of Patients with 
Rosacea (n=40)
Sex, n (%)
    Male 10 (25)
    Female 30 (75)
Age (yrs) 47.2±13.8 (21‒76)
    Male, mean±SD (range) 45.1±17.1 (24‒65)
    Female, mean±SD (range) 47.9±12.7 (21‒76)
Clinical type, n (%)
    Erythemato-telangiectatic 12 (30)
    Papulopustular 28 (70)
Clinical grading (1‒3), n (%) 
    1. Mild   6 (15)
    2. Moderate 24 (60)
    3. Severe 10 (25)
Table 2. Immunohistochemical Staining According to Clini-
cal Grade
Clinical grade
p value
1 (n=6) 2 (n=24) 3 (n=10)
Overall 
  inflammation 
1.9±0.2 2.1±0.4 2.4±0.5 0.018 
PAR-2 (0-3) 1.0±0.9 2.1±0.6 1.4±0.8 0.894
Cathelicidin 
  (0-3)
1.9±0.7 2.0±0.5 1.4±0.8 0.054
PAR-2, protease-activated receptor-2.
Fig. 1. Significant correlation was observed between PAR-2 and cathelici-
din expression in rosacea (R=0.330, p=0.037). PAR-2, protease-activated re-
ceptor-2.
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ciated with Demodex folliculorum infestation, are suspected 
to activate immune responses in patients predisposed to ro-
nent vasodilation in the affected skin may explain the persi-
stent erythema.19 Microbial agents, notably bacteria asso-
Fig. 2. Clinical picture of a 38-year-old male patient with papulopustular rosacea (A) and immunohistochemical findings of PAR-2 (B) and 
cathelicidin (C) (H&E, ×400). Staining intensity of PAR-2, 2.5; cathelicidin, 2.5. Cathelicidin staining on normal skin tissue (staining intensity, 
0) (D). PAR-2, protease-activated receptor-2.
Fig. 3. Clinical picture of a 69-year-old female patient with papulopustular rosacea (A) and immunohistochemical findings of PAR-2 (B) 
and cathelicidin (C) (H&E, ×400). Staining intensity of PAR-2, 2.5; cathelicidin 3. Cathelicidin staining on normal skin tissue (staining intensi-
ty, 0) (D). PAR-2, protease-activated receptor-2.
A
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D
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Initially, we found significantly higher cathelicidin expres-
sion in rosacea skin tissues than in normal skin, although 
PAR-2 expression did not differ significantly between nor-
mal skin and rosacea. Cathelicidin expression also showed a 
significant positive correlation with PAR-2 expression on im-
munohistochemical staining. These findings may plausibly 
reflect an interaction between PAR-2 and cathelicidin in the 
pathogenesis of rosacea. Additionally, both cathelicidin and 
PAR-2 receptor mRNA and protein increased in keratino-
cytes treated with PAR-2 AP in vitro. These results suggested 
sacea.20,21 Altered adaptive and innate immune responsive-
ness and enhanced cellular reactivity are hypothesized. Ab-
normal innate immunity is suggested by detection of an 
AMP and its processing serine protease at higher levels in 
rosacea lesions than in normal skin.8 In the present study, 
we tested the involvement of PAR-2 in the expression of 
AMPs that may contribute to rosacea. 
Two important and well-studied types of AMPs in human 
skin are defensins and cathelicidin LL-37.22,23 hBD-2, the 
first AMP characterized in human skin, is induced in skin 
inflammation and infection, and is most effective against 
gram-negative bacteria.24 Human cathelicidin LL-37, active 
against both gram-positive and gram-negative bacteria, may 
be detected directly in human skin only at sites of inflamma-
tion.25 Additional functions of LL-37 include chemotactic 
activation and modulation of cytokines and inflammatory 
mediators such as cyclooxygenase-2, pro-interleukin (IL) 
1b, and IL-8 in keratinocytes.26 Aberrant LL-37 expression 
at inflammatory sites modifies dendritic cell differentiation, 
thereby linking innate and adaptive immune responses. The 
LL-37-activated dendritic cells may potentiate expression 
of co-stimulatory molecules and a Th1 response in vitro.27 
In cultured endothelial cells, LL-37 induces angiogenesis 
and triggers the proliferation of vessel-like structures.6 Ef-
fects induced in vitro by LL-37 correspond to changes seen 
in rosacea, and altered cathelicidin expression is observed 
in rosacea-affected skin.8 Although the regulation of cathe-
licidin LL-37 production is incompletely understood, pro-
teolytic processing of a precursor protein is essential for its 
activation as a pro-inflammatory molecule.28 The abundance 
of LL-37 in the lesions of rosacea may result through abnor-
mal production or activity of an epidermal serine protease or 
of kallikrein, which process the cathelicidin precursor.8,9 Cat-
helicidin LL-37 is subject to regulation by various factors, in-
cluding cytokines, bacterial metabolites such as butyrate, hy-
poxia, and exposure to the sunlight through up-regulation of 
human cathelicidin antimicrobial protein (hCAP18) expres-
sion by vitamin D3.29-32 
The PARs comprise a subfamily of G protein-coupled, 
7-transmembrane domain receptors.12,33 PAR-1, -3, and -4 are 
activated by thrombin, whereas PAR-2 is activated by tryp-
sin-like serine proteases such as kallikrein. Epidermal cells 
produce several kallikreins, including kallikrein 5 and kalli-
krein 14, which activate PAR-2.14,34 Detection of PAR-2 and 
kallikrein 14 in rosacea lesions has been widely reported.35 
From this we hypothesized that direct activation of PAR-2 in 
rosacea lesions may increase cathelicidin expression.
Fig. 4. Effect of PAR-2 AP on the mRNA expression of PAR-2, cathelicidin 
and VEGF in HaCaT cells. Real time RT-PCR of PAR-2, cathelicidin and VEGF 
in HaCaT cells after PAR-2 activating peptide and PAR-2 control peptide 
treatment. Each data point represents the mean (±SEM) result from three in-
dependent experiments. *p<0.05. AP, activating peptide; CP, control peptide; 
VEGF, vascular endothelial growth factor; PAR-2, protease-activated re-
ceptor-2; SEM, standard error of the mean. 
Fig. 5. Effect of PAR-2 AP on the expression of PAR-2, cathelicidin and 
VEGF proteins in HaCaT cells. Western blotting against PAR-2, cathelicidin 
and VEGF in HaCaT cells after PAR-2 activating peptide and PAR-2 control 
peptide treatment. AP, activating peptide; CP, control peptide; GAPDH, glyc-
eraldehyde phosphate dehydrogenase; PAR-2, protease-activated recep-
tor-2; VEGF, vascular endothelial growth factor.
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tissues are needed for such assay. 
Based on our results, we postulated that increased ex-
pression of PAR-2 and serine proteases induced by exoge-
nous irritants and aggravating factors may lead to produc-
tion of cathelicidin itself through PAR-2 signaling and to 
excessive LL-37 production through processing by serine 
proteases and that both pathways contribute to the patholo-
gy of rosacea. In conclusion, PAR-2 may contribute to the 
pathogenesis of rosacea through regulatory action of innate 
immune response. Molecular antagonists of PAR-2 present 
a plausible therapeutic intervention for rosacea. 
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